Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome)

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

BioMarin Pharmaceutical
1 program
Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)N/A1 trial
Active Trials
NCT00214773Completed237Est. May 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BioMarin PharmaceuticalMucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)

Clinical Trials (1)

Total enrollment: 237 patients across 1 trials

NCT00214773BioMarin PharmaceuticalMucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)

Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)

Start: Jul 2005Est. completion: May 2020237 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space